762285-67-6

Upstream product

• 169749-99-9 (3S)-(-)-1-benzyl-3-(methylamino)pyrrolidine 
• 181146-88-3 4'-(trifluoromethyl)-4-biphenylcarbonyl chloride 
• 762285-66-5 C₁₉H₂₁BrN₂O 
• 128796-39-4 4-trifluoromethylphenylboronic acid 

Downstream Products

• 764722-59-0 ((R)-1-{(S)-3-[Methyl-(4'-trifluoromethyl-biphenyl-4-carbonyl)-amino]-pyrrolidine-1-carbonyl}-pyrrolidin-3-yl)-carbamic acid tert-butyl ester 
• 910220-80-3 4'-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-[(S)-1-((R)-3-methylamino-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-amide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1

The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited potent binding affinity and functional activity at MCH-R1, and good oral bioavailability in rat.

MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R1, R2, R3, R4, and R5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.